Fax Form Updates

Form to Update	Non-Preferred	Preferred	Language to insert after "For All Requests" section
https://www.aetnabetterhealth.com/virginia- hmosnp/assets/pdf/providers/hmo-snp/FaxForms/69265- 4 Eylea FINAL 12-8-19.pdf	Eylea	Avastin or Avastin biosimilar	or bevacizumab biosimilar?
https://www.aetnabetterhealth.com/virginia- hmosnp/assets/pdf/providers/hmo-snp/FaxForms/69275- 4 Lucentis FINAL 12-8-19.pdf	Lucentis	Avastin or Avastin biosimilar	For All Medicare Requests: 1. Yes No Has the patient had prior therapy with Lucentis (ranibizumab) within the last 365 days? 2. Yes No Has the patient had a trial, intolerance, or contraindication to Avastin (bevacizumab) or bevacizumab biosimilar? 3. Please explain if there are any medical reason(s) that the patient cannot use Avastin (bevacizumab) or bevacizumab biosimilar.
https://www.aetnabetterhealth.com/virginia- hmosnp/assets/pdf/providers/hmo-snp/FaxForms/68744- 4 Visco FINAL 12-8-19.pdf	Durolane, Euflexxa, Gelsyn-3, GenVisc, Hyalgan, Hymovis, Monovisc, Orthovisc, Supartz, Synvisc, Synvisc One, TriVisc	Visco-3, or Gel-One	, , , , , , , , , , , , , , , , , , , ,
https://www.aetnabetterhealth.com/virginia- hmosnp/assets/pdf/providers/hmo-snp/FaxForms/68694- 4 Denosumab(Xgeva) FINAL 12-8-19.pdf	Xgeva	Pamidronate, or zoledronic acid	For All Medicare Requests: 1. Yes No Has the patient had prior therapy with Xgeva (denosumab) within the last 365 days? 2. Yes No Has the patient had a trial, intolerance, or contraindication to pamidronate or zoledronic acid? 3. Please explain if there are any medical reason(s) that the patient cannot use pamidronate or zoledronic acid.
https://www.aetnabetterhealth.com/virginia- hmosnp/assets/pdf/providers/hmo-snp/FaxForms/68979- 4 Herceptin FINAL 12-8-19.pdf	Herceptin, Herceptin Hylecta	Herceptin Biosimilar	For All Medicare Requests: 1. Yes No Has the patient had prior therapy with Herceptin (trastuzumab) or Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) within the last 365 days? 2. Yes No Has the patient had a trial, intolerance, or contraindication to biosimilar trastuzumab? 3. Please explain if there are any medical reason(s) that the patient cannot use biosimilar trastuzumab.
https://www.aetnabetterhealth.com/virginia- hmosnp/assets/pdf/providers/hmo-snp/FaxForms/69389- 4 Neupogen FINAL 12-8-19.pdf	Neupogen	Zarxio	For All Medicare Requests: 1. Yes No Has the patient had prior therapy with Neupogen (filgrastim) within the last 365 days? 2. Yes No Has the patient had a trial, intolerance, or contraindication to Zarxio (filgrastim-sndz)? 3. Please explain if there are any medical reason(s) that the patient cannot use Zarxio (filgrastim-sndz).
https://www.aetnabetterhealth.com/virginia- hmosnp/assets/pdf/providers/hmo-snp/FaxForms/69403- 4 Nivestym FINAL 12-8-19.pdf	Nivestym	Zarxio	For All Medicare Requests: 1. □ Yes □ No Has the patient had prior therapy with Nivestym (filgrastim-aafi) within the last 365 days? 2. □ Yes □ No Has the patient had a trial, intolerance, or contraindication to Zarxio (filgrastim-sndz)? 3. Please explain if there are any medical reason(s) that the patient cannot use Zarxio (filgrastim-sndz).

https://www.aetnabetterhealth.com/virginia- hmosnp/assets/pdf/providers/hmo-snp/FaxForms/69388- 4 Granix_FINAL_12-8-19.pdf	Granix	Zarxio	For All Medicare Requests: 1. □ Yes □ No Has the patient had prior therapy with Granix (tbo-filgrastim) within the last 365 days? 2. □ Yes □ No Has the patient had a trial, intolerance, or contraindication to Zarxio (filgrastim-sndz)? 3. Please explain if there are any medical reason(s) that the patient cannot use Zarxio (filgrastim-sndz).
https://www.aetnabetterhealth.com/virginia- hmosnp/assets/pdf/providers/hmo-snp/FaxForms/69391- 4 Neulasta FINAL 12-8-19.pdf	Neulasta, Neulasta Onpro	Udenyca	For All Medicare Requests: 1. □ Yes □ No Has the patient had prior therapy with Neulasta (pegfilgrastim) within the last 365 days? 2. □ Yes □ No Has the patient had a trial, intolerance, or contraindication to Udenyca (pegfilgrastim-cbqv)? 3. Please explain if there are any medical reason(s) that the patient cannot use Udenyca (pegfilgrastim-cbqv).
https://www.aetnabetterhealth.com/virginia- hmosnp/assets/pdf/providers/hmo-snp/FaxForms/69395- 4 Fulphila FINAL 12-8-19.pdf	Fulphila	Udenyca	For All Medicare Requests: 1. □ Yes □ No Has the patient had prior therapy with Fulphila (pegfilgrastim-jmdb) within the last 365 days? 2. □ Yes □ No Has the patient had a trial, intolerance, or contraindication to Udenyca (pegfilgrastim-cbqv)? 3. Please explain if there are any medical reason(s) that the patient cannot use Udenyca (pegfilgrastim-cbqv).
https://www.aetnabetterhealth.com/virginia- hmosnp/assets/pdf/providers/hmo-snp/FaxForms/68305- 4%20IVIG_FINAL_12-8-19.pdf	Bivigam, Carimune NF, Cuvitru, Flebogamma, Gammagard, Gammaked, Gammaplex, Gamunex-C, Hyqvia, Octagam, Panzyga	Privigen, or Hizentra	For All Medicare Requests: 1. □ Yes □ No Has the patient had prior therapy with immune globulin therapy within the last 365 days? 2. □ Yes □ No Has the patient had a trial, intolerance, or contraindication to Privigen or Hizentra? 3. Please explain if there are any medical reason(s) that the patient cannot use Privigen or Hizentra.
			For All Medicare Requests:
https://www.aetnabetterhealth.com/virginia- hmosnp/assets/pdf/providers/hmo-snp/FaxForms/68425- 4 ESA Agents FINAL 12-8-19.pdf	Procrit, Epogen, Aranesp	Retacrit	 Yes No Has the patient had prior therapy with Aranesp (darbepoetin alfa), Epogen (epoetin alfa), or Procrit (epoetin alfa) within the last 365 days? Yes No Has the patient had a trial, intolerance, or contraindication to Retacrit (epoetin alfaepbx)? Please explain if there are any medical reason(s) that the patient cannot use Retacrit (epoetin alfaepbx).
hmosnp/assets/pdf/providers/hmo-snp/FaxForms/68425-	Procrit, Epogen, Aranesp Botox, Myobloc, Xeomin	Retacrit	alfa), or Procrit (epoetin alfa) within the last 365 days? 2. Yes No Has the patient had a trial, intolerance, or contraindication to Retacrit (epoetin alfaepbx)? 3. Please explain if there are any medical reason(s) that the patient cannot use Retacrit (epoetin alfaepoetin al
hmosnp/assets/pdf/providers/hmo-snp/FaxForms/68425- 4 ESA Agents FINAL 12-8-19.pdf https://www.aetnabetterhealth.com/virginia-hmosnp/assets/pdf/providers/hmo-snp/FaxForms/68776-			alfa), or Procrit (epoetin alfa) within the last 365 days? 2. Yes No Has the patient had a trial, intolerance, or contraindication to Retacrit (epoetin alfaepbx)? 3. Please explain if there are any medical reason(s) that the patient cannot use Retacrit (epoetin alfaepbx). For All Medicare Requests: 1. Yes No Has the patient had prior therapy with Botox (onabotulinumtoxinA), Myobloc (rimabotulinumtoxinB), or Xeomin (incobotulinumtoxinA) within the last 365 days? 2. Yes No Has the patient had a trial, intolerance, or contraindication to Dysport (AbobotulinumtoxinA)? 3. Please explain if there are any medical reason(s) that the patient cannot use Dysport

			 2. — Yes — No Has the patient had a trial, intolerance, or contraindication to docetaxel or generic paclitaxel? 3. Please explain if there are any medical reason(s) that the patient cannot use docetaxel or generic paclitaxel.
https://www.aetnabetterhealth.com/virginia- hmosnp/assets/pdf/providers/hmo-snp/FaxForms/69256- 4_Lemtrada_FINAL_12-8-19.pdf	Lemtrada	Tysabri	For All Medicare Requests: 1. □ Yes □ No Has the patient had prior therapy with Lemtrada (alemtuzumab) within the last 365 days? 2. □ Yes □ No Has the patient had a trial, intolerance, or contraindication to Tysabri (natalizumab)? 3. Please explain if there are any medical reason(s) that the patient cannot use Tysabri (natalizumab).
https://www.aetnabetterhealth.com/virginia- hmosnp/assets/pdf/providers/hmo-snp/FaxForms/69492- 4 Evenity FINAL 12-8-19.pdf	Evenity	Prolia (MA), Forteo (MAPD)	For All Medicare Requests: 1. □ Yes □ No Has the patient had prior therapy with Evenity (romosozumab-aqqg) within the last 365 days? 2. □ Yes □ No Has the patient had a trial, intolerance, or contraindication to Prolia (denosumab)? 3. □ Yes □ No Has the patient had a trial, intolerance, or contraindication to Forteo (teriparatide)? 4. Please explain if there are any medical reason(s) that the patient cannot use Prolia (denosumab). 5. Please explain if there are any medical reason(s) that the patient cannot use Forteo (teriparatide).
https://www.aetnabetterhealth.com/virginia- hmosnp/assets/pdf/providers/hmo-snp/FaxForms/68846- 4_Actemra_FINAL_12-8-19.pdf f	Actemra	Renflexis (MA), Humira (MAPD)	For All Medicare Requests: 1. □ Yes □ No Has the patient had prior therapy with Actemra (tocilizumab) within the last 365 days? 2. □ Yes □ No Has the patient had a trial, intolerance, or contraindication to Renflexis (infliximababda)? 3. □ Yes □ No Has the patient had a trial, intolerance, or contraindication to Humira (adalimumab)? 4. Please explain if there are any medical reason(s) that the patient cannot use Renflexis (infliximababda). 5. Please explain if there are any medical reason(s) that the patient cannot use Humira (adalimumab).
https://www.aetnabetterhealth.com/virginia- hmosnp/assets/pdf/providers/hmo-snp/FaxForms/69012- 4 Entyvio FINAL 12-8-19.pdf	Entyvio	Renflexis (MA), Humira (MAPD)	For All Medicare Requests: 1. □ Yes □ No Has the patient had prior therapy with Entyvio (vedolizumab) within the last 365 days? 2. □ Yes □ No Has the patient had a trial, intolerance, or contraindication to Renflexis (infliximababda)? 3. □ Yes □ No Has the patient had a trial, intolerance, or contraindication to Humira (adalimumab)? 4. Please explain if there are any medical reason(s) that the patient cannot use Renflexis (infliximababda). 5. Please explain if there are any medical reason(s) that the patient cannot use Humira (adalimumab).
https://www.aetnabetterhealth.com/virginia- hmosnp/assets/pdf/providers/hmo-snp/FaxForms/69493- 4 Ilumya FINAL 12-8-19.pdf	Ilumya	Renflexis (MA), Humira (MAPD)	For All Medicare Requests: 1.
https://www.aetnabetterhealth.com/virginia- hmosnp/assets/pdf/providers/hmo-snp/FaxForms/69299- 4 Inflectra FINAL 12-8-19.pdf	Inflectra	Renflexis (MA), Humira (MAPD)	For All Medicare Requests: 1. □ Yes □ No Has the patient had prior therapy with Inflectra (infliximab-dyyb) within the last 365 days? 2. □ Yes □ No Has the patient had a trial, intolerance, or contraindication to Renflexis (infliximab-abda)? 3. □ Yes □ No Has the patient had a trial, intolerance, or contraindication to Humira (adalimumab)? 4. Please explain if there are any medical reason(s) that the patient cannot use Renflexis (infliximab-abda).

			5. Please explain if there are any medical reason(s) that the patient cannot use Humira (adalimumab).
https://www.aetnabetterhealth.com/virginia- hmosnp/assets/pdf/providers/hmo-snp/FaxForms/68852- 4_Orencia_FINAL_12-8-19.pdf	Orencia	Renflexis (MA), Humira (MAPD)	For All Medicare Requests: 1. □ Yes □ No Has the patient had prior therapy with Orencia (abatacept) within the last 365 days? 2. □ Yes □ No Has the patient had a trial, intolerance, or contraindication to Renflexis (infliximababda)? 3. □ Yes □ No Has the patient had a trial, intolerance, or contraindication to Humira (adalimumab)? 4. Please explain if there are any medical reason(s) that the patient cannot use Renflexis (infliximababda). 5. Please explain if there are any medical reason(s) that the patient cannot use Humira (adalimumab).
https://www.aetnabetterhealth.com/virginia- hmosnp/assets/pdf/providers/hmo-snp/FaxForms/68855- 4 Remicade FINAL 12-8-19.pdf	Remicade	Renflexis (MA), Humira (MAPD)	For All Medicare Requests: 1. □ Yes □ No Has the patient had prior therapy with Remicade (infliximab) within the last 365 days? 2. □ Yes □ No Has the patient had a trial, intolerance, or contraindication to Renflexis (infliximababda)? 3. □ Yes □ No Has the patient had a trial, intolerance, or contraindication to Humira (adalimumab)? 4. Please explain if there are any medical reason(s) that the patient cannot use Renflexis (infliximababda). 5. Please explain if there are any medical reason(s) that the patient cannot use Humira (adalimumab).
https://www.aetnabetterhealth.com/virginia- hmosnp/assets/pdf/providers/hmo-snp/FaxForms/69354- 4 Renflexis FINAL 12-8-19.pdf	Renflexis	Humira (MAPD)	For Medicare MAPD Requests: 1. □ Yes □ No Has the patient had prior therapy with Renflexis (infliximab-abda) within the last 365 days? 2. □ Yes □ No Has the patient had a trial, intolerance, or contraindication to Humira (adalimumab)? 3. Please explain if there are any medical reason(s) that the patient cannot use Humira (adalimumab).
https://www.aetnabetterhealth.com/virginia- hmosnp/assets/pdf/providers/hmo-snp/FaxForms/68535- 4 Rituxan FINAL 12-8-19.pdf	Rituxan	Renflexis (MA), Humira (MAPD)	For All Medicare Requests: 1. Yes No Has the patient had prior therapy with Rituxan (rituximab) within the last 365 days? 2. Yes No Has the patient had a trial, intolerance, or contraindication to Renflexis (infliximababda)? 3. Yes No Has the patient had a trial, intolerance, or contraindication to Humira (adalimumab)? 4. Please explain if there are any medical reason(s) that the patient cannot use Renflexis (infliximababda). 5. Please explain if there are any medical reason(s) that the patient cannot use Humira (adalimumab).
https://www.aetnabetterhealth.com/virginia- hmosnp/assets/pdf/providers/hmo-snp/FaxForms/68854- 4 Stelara FINAL 12-8-19.pdf	Stelara	Renflexis (MA), Humira (MAPD)	For All Medicare Requests: 1.
https://www.aetnabetterhealth.com/virginia- hmosnp/assets/pdf/providers/hmo-snp/FaxForms/69264- 4 Tysabri FINAL 12-8-19.pdf	Tysabri	Renflexis (MA), Humira (MAPD)	For All Medicare Requests: 1. Yes No Has the patient had prior therapy with Tysabri (natalizumab) within the last 365 days? 2. Yes No Has the patient had a trial, intolerance, or contraindication to Renflexis (infliximababda)? 3. Yes No Has the patient had a trial, intolerance, or contraindication to Humira (adalimumab)? 4. Please explain if there are any medical reason(s) that the patient cannot use Renflexis (infliximababda). 5. Please explain if there are any medical reason(s) that the patient cannot use Humira (adalimumab).

	Category	Non-Preferred	Preferred
	Ophthalmic Disorders	Eylea, Lucentis	Avastin, or biosimilar
	Viscosupplements	Durolane, Euflexxa, Gelsyn-3, GenVisc, Hyalgan, Hymovis, Monovisc, Orthovisc, Supartz, Synvisc, Synvisc One, TriVisc	Visco-3, or Gel-One
	Bone Resorption Inhibitors	Xgeva	Pamidronate, or zoledronic acid
	Immunologics (MA Only)	Actemra, Entyvio, Ilumya, Inflectra, Orencia, Remicade, Rituxan, Stelara, Tysabri	Renflexis
	Oncology	Herceptin, Hylecta	Herceptin Biosimilar
B/B	CSF- Leukocyte Growth Factors	Neulasta, Neulasta Onpro, Fulphila	Udenyca
B/		Neupogen, Nivestym, Granix	Zarxio
	IVIG/SQIG	Bivigam, Carimune NF, Cuvitru, Flebogamma, Gammagard, Gammaked, Gammaplex, Gamunex-C, Hyqvia, Octagam, Panzyga	Privigen, or Hizentra
	Erythropoiesis Stimulating Agents	Procrit, Epogen, Aranesp	Retacrit
	Botulinum Toxins	Botox, Myobloc, Xeomin	Dysport
	РАН	Remodulin	Generic Remodulin
	Neoplasms	Abraxane	Docetaxel, or paclitaxel
	Multiple Sclerosis	Lemtrada	Tysabri

	Bone Resorption Inhibitors (MA Only)	Evenity	Prolia
	Immunologics (MAPD Only)	Actemra, Entyvio, Ilumya, Inflectra, Orencia, Remicade, Renflexis, Rituxan, Stelara, Tysabri	Humira
B/D	Bone Resorption Inhibitors (MAPD Only)	Evenity	Forteo